Older Age and HIV-Associated Neurocognitive Disorder (HAND) (10/17/17)

  • Assessing for HIV-Associated Neurocognitive Disorder (HAND) is important and a two-tiered approach– first assessing symptoms with follow-up testing as needed is a reasonable paradigm to follow for busy practices
  • Older HIVadults living with HIV are a heterogeneous group with many factors and comorbidities that should be considered beyond HIV itself as causes and potential targets for treatment of cognitive impairment
  • No first line treatment for HAND has been established; however emerging research suggests several behavioral strategies may be effective in delaying, preventing, or improving the course of HAND

HAND, Aging, & Risk Factors

HIV-associated neurocognitive disorder (HAND) remains a frequent problem despite effective antiretroviral therapy. Up to 50% of HIV patients will exhibit HAND upon neuropsychological (NP) testing;  however, only about a quarter of these patients will endorse everyday symptoms and less than half of those are estimated to have HIV-associated dementia (HAD)[1]. One large longitudinal study of PLWH showed that over an average of 35 months, 22.7% of participants neurocognitive status declined, 60.8% remained stable, and 16.5% improved[2].  Risk factors for neuropsychologic impairment include previous CNS disease, low nadir CD4 cell count, detectable plasma viral load, and low current CD4 cell count[1, 3]. Co-existing  morbidities also contribute to poorneuropsychological performance, including diabetes, hypertension, HCV co-infection,  medication toxicities, inflammation, psychoactive substance use disorders, and psychaitric disorders[2, 4, 5]. There is evidence for aging as a risk factor for HAND[6-9]. This association of aging with HAND appears to be dependent  upon the level of severity of HAND – greatest  with HIV-associated dementia (HAD), less prominent with Mild Neurocognitive Disorder (MND — formerly minor cognitive-motor disorder)[5, 10-12] and least consistent with overall cognitive  impairment[10, 12-14]. There is mixed evidence on whether HIV accelerates normal aging, or whether it accenuates aging via additional risk factors[15, 16]. Yet a recent study found that independent of aging, HIV was associated with an almost 5-fold risk for developing incident cognitive impairment[17]. Among older PLWH, one must also consider concurrent neurodegenerative disorders, principally Alzheimer’s disease, mild cognitive impairment(MCI)[17], and the cognitive impact of cerebrovascular disease[7, 8].

HAND Criteria

The current most widely used nosology for HAND in research studies is the Frascati criteria[18]. A diagnosis of HAD requires: (a) acquired moderate-to-severe neuropsychological (NP) impairment, documented by a score at least 2 SDs below demographically corrected normative means in at least 2 cognitive domains, (b) moderate-to-severe difficulty in functional status in activities of daily living due specifically to this impairment, (c) a duration of at least one month, (d) absence of delirium and (e) absence of confounding conditions capable of otherwise explaining the impairment. Mild Neurocognitive Disorder (MND) is defined by: (a) an acquired mild level of NP impairment documented by a score of at least 1 SD below demographically-corrected norms on tests in at least 2 cognitive domains, (b) the impairment interferes at a mild level with functional status, and (c) through (e) – as above for  HAD. Asymptomatic Neurocognitive Impairment (ANI) requires the same level of cognitive impairment as MND, but without any functional deficit. The differential diagnosis of these diagnostic entities cannot be determined by screening instruments but require more in-depth NP and functional assessment. However, brief clinical screening techniques can and should be employed before more formal and comprehensive NP testing is sought.

Note that while the Frascati criteria are considered the gold standard, other criteria have emerged (e.g., DSM-5), yet there is little literature on their application. While some criteria have been proposed to address criticism that the Frascati criteria (and DSM-5 criteria) are too sensetive and thus overestimate HAND[19], there is longitudinal evidence that even ANI poses a significant risk for earlier development of symptomatic HAND[20]. Thus identifying those with such subtle impairment may have prognostic value in clinical settings and provide and opportunity to intervene and delay the progression of HAND.Symptoms of HAND often include deficits in attention, executive function (such as planning, organization, multi-tasking) and slowing.

Cognitive Screening and HAND

Given the high frequency of HAND and its association with important functional outcomes such as adherence to antiretroviral medications, cognitive screening is clinically important. A two-tiered approach assessing symptoms with follow-up testing is a reasonable paradigm to follow for busy practices, although screening of all patients is recommended whenever possible.

The demonstrated disease heterogeneity and the relatively high frequency of asymptomatic cognitive impairment must inform sensitive screening approaches in order to be effective, and the selection of optimal screening instruments remains an issue in the field to date[5].

Currently, simple screening instruments exist for the most severe form of HAND (i.e., HAD), Alzheimer’s disease (AD) and vascular  cognitive impairment. However, the overlap  in content of these tests is necessarily limited given the differing presentations, particularly for AD (primarily cortical impairmentversus HAND  (primarily sub-cortical impairment). Thus, optimal  screening strategies for older HIV infected  adults need to cover broader areas than  individual screens allow. Unfortunately, the  tests designed to identify HAD (such as HIV Dementis Scale or HDS) perform  considerably less well for milder conditions  (MND and ANI) and cannot be recommended for screening and may need to be supplemented by other tests (such as the Trail Making Test)[5, 21, 22] for this purpose.

The Montreal Cognitive Assessment (MoCA)  Test may be the best suited screening instrument for an older HIV infected population, as it taps areas of cognitive performance involving executive functioning and other higher cognitive abilities thought to be most vulnerable in milder HAND, while remaining broad enough to detect diseases such as AD. The MoCA has also demonstrated associations with self-reported and clinician-rated everyday functioning (i.e., Karnofsky scores)[23] in older HIV positive-infected adults.  However, validation studies in younger and older samples of PLWH suggest this test does have sizable limitations; including lack of information processing  speed and motor skills components and poor specificity resulting in a high false positive rate (particularly among educationally disadvanategd patients)[24]. Thus, clinicians should avoid using such cognitive screening tools as stand-alone diagnostic tools, but instead for determining which patients should be referred for comprehensive NP evaluation to clinically diagnose HAND. The HIV Dementia Scale (HDS) is a well established test from the pre-ART era; however most studies in the current era demonstrate that it fails to identify all but the more severe forms of impairment. The International HIV Dementia Scale (IHDS) is useful within the USA for patients from other cultures, of which Hispanics would be the most common, but maintains similar limitations as does the HDS[25-30]. Similarly, the Mini Mental State Examination does not tap domains that are most impaired in HAND (i.e., executive) and has been shown less effective than MoCA, and thus is not recommended for screening in this setting.


Currently, consensus recommendations on the treatment of HAND are concordant in a focus on the use of a stable, effective ART regimen. Beyond this, the American Psychiatric Association Practice Guidelines for HIV/AIDS[31] and the Guide for HIV/AIDS Clinical Care (DHHS, 2011) recommend the use of CNS-penetrating antiretroviral therapy regimens and psychostimulants. However, it should be noted that there is considerable variability in how this approach is applied since there are no large-scale intervention trials that have consistently demonstrated efficacy for these recommendations. Furthermore, mixed findings exist on whether CNS-penetrating therapies have a beneficial effect on neurocognitive outcomes and some studies suggest these reigimens may be neurotoxic[32]. A recent pilot study found that a maraviroc (a CCR5 chemokine co-receptor) enhanced ART regimen improved cognitive functioning in patients with HAND[33].

These approaches need to be considered in the context of medication side-effects, antiretroviral adherence and the risk of exposure to new medications that could alter resistance profiles and long-term HIV  outcomes. More research is needed. Cognitive impairment in patients with HIV is often multifactorial, thus an exclusionary work-up for non-HIV-associated treatable causes of neurocognitive disorder, such as thyroid disease, syphilis, and B12  deficiency, psychiatric comorbidites and substance use disorders, as well as conditions specific to HIV infection is important. Patients with presentations suggestive of CNS opportunistic infection or tumor, such as focal neurological findings, require careful evaluation, as do cases with more rapid neurological progression. Use of medications with higher CNS penetration effectiveness have clearly demonstrated utility in these focused situations, particularly in rare cases of CNS escape where virus is identified in CSF despite suppression in plasma. In addition, psychostimulants have some evidence for  efficacy in smaller studies[14, 34-36] . Other therapies that have shown promise in research studies include the use  of anti-inflammatory agents, neurotrophic  factors, nutritional supplements, and  antioxidants, although recent studies using both minocycline as a novel antioxidant and lithium[37] did not demonstrate efficacy on HAND. More research is clearly needed.

Based on general recommendations applied to HIV-negative populations, exercise (both physical and mental), remaining socially engaged[38, 39], cognitive remediation therapy[40], non-invasive brain stimulation[41], monitoring for depression, and monitoring for cerebrovascular risk factors are relatively safe and possibly effective adjunctive strategies, some of which are beginning to be examined in PLWH.While cognitive and behavioral interventions targeting lifestyle factors are needed, such approaches to preventing and improving HAND may be beneficial above pharmacologic approaches in a population already burdened by polypharmacy. While the prevalence of HAND is high, there nonetheless continues to be a subset of PLWH who are free from such cognitive and functional impairments[42], leading to a new focus in research on successful cognitive aging in this population and factors that might contribute to such a phenotype and thus inform treatment and prevention approaches for HAND.

Updated by Pariya Fazeli Wheeler PhD

The University of Alabama at Birmingham School of Nursing

June 2017


  1. Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010; 75(23):2087-2096.
  2. Heaton RK, Franklin DR, Jr., Deutsch R, Letendre S, Ellis RJ, Casaletto K, et al. Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 2015; 60(3):473-480.
  3. Cysique LA, Murray JM, Dunbar M, Jeyakumar V, Brew BJ. A screening algorithm for HIV-associated neurocognitive disorders. HIV Med 2010; 11(10):642-649.
  4. Nasi M, De Biasi S, Gibellini L, Bianchini E, Pecorini S, Bacca V, et al. Aging and inflammation in patients with HIV infection. Clin Exp Immunol 2016.
  5. Goodkin K. Psychiatric Aspects of HIV Spectrum Disease. Focus: The Journal of Lifelong Learning in Psychiatry 2009; 7(3):303.
  6. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11(1):39-44.
  7. Valcour VaSCaSBaWMaPPaSOaHPaGJaSN. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63(5):822–827.
  8. Valcour VG, Shikuma CM, Watters MR, Sacktor NC. Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 2004; 18 Suppl 1:S79-86.
  9. McArthur JC, Hoover DR, Bacellar H, Miller EN, Cohen BA, Becker JT, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 1993; 43(11):2245-2252.
  10. Cherner M, Ellis RJ, Lazzaretto D, Young C, Mindt MR, Atkinson JH, et al. Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004; 18 Suppl 1:S27-34.
  11. Larussa D, Lorenzini P, Cingolani A, Bossolasco S, Grisetti S, Bongiovanni M, et al. Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. AIDS Res Hum Retroviruses 2006; 22(5):386-392.
  12. Wilkie FL, Goodkin K, Khamis I, van Zuilen MH, Lee D, Lecusay R, et al. Cognitive functioning in younger and older HIV-1-infected adults. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S93-S105.
  13. Hardy DJ, Hlnklnt CH, Satz P, Stenquist PK, Gorp WGV, Moore LH. Age Differences and Neurocognitive Performance in HIV-Infected Adults. New Zealand Journal of Psychology 1999; 28(2).
  14. Hinkin CH, Castellon SA, Atkinson JH, Goodkin K. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol 2001; 54 Suppl 1:S44-52.
  15. Cole JH, Underwood J, Caan MW, De Francesco D, van Zoest RA, Leech R, et al. Increased brain-predicted aging in treated HIV disease. Neurology 2017; 88(14):1349-1357.
  16. Pathai S, Bajillan H, Landay AL, High KP. Is HIV a model of accelerated or accentuated aging? J Gerontol A Biol Sci Med Sci 2014; 69(7):833-842.
  17. Sheppard DP, Iudicello JE, Bondi MW, Doyle KL, Morgan EE, Massman PJ, et al. Elevated rates of mild cognitive impairment in HIV disease. J Neurovirol 2015; 21(5):576-584.
  18. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69(18):1789-1799.
  19. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011; 11:356.
  20. Grant I, Franklin DR, Jr., Deutsch R, Woods SP, Vaida F, Ellis RJ, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 2014; 82(23):2055-2062.
  21. Chalermchai T, Valcour V, Sithinamsuwan P, Pinyakorn S, Clifford D, Paul RH, et al. Trail Making Test A improves performance characteristics of the International HIV Dementia Scale to identify symptomatic HAND. J Neurovirol 2013; 19(2):137-143.
  22. Goodkin K. Psychiatric disorders in HIV-spectrum illness. Tex Med 1988; 84(9):55-61.
  23. Fazeli PL, Casaletto KB, Paolillo E, Moore RC, Moore DJ, The Hnrp G. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning. J Clin Exp Neuropsychol 2017; 39(9):842-853.
  24. Fazeli PL, Casaletto KB, Paolillo E, Moore RC, Moore DJ, The Hnrp G. Screening for neurocognitive impairment in HIV-positive adults aged 50 years and older: Montreal Cognitive Assessment relates to self-reported and clinician-rated everyday functioning. J Clin Exp Neuropsychol 2017:1-12.
  25. Bottiggi KA, Chang JJ, Schmitt FA, Avison MJ, Mootoor Y, Nath A, et al. The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci 2007; 260(1-2):11-15.
  26. Davis HF, Skolasky RL, Jr., Selnes OA, Burgess DM, McArthur JC. Assessing HIV-associated dementia: modified HIV dementia scale versus the Grooved Pegboard. AIDS Read 2002; 12(1):29-31, 38.
  27. Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005; 19(13):1367-1374.
  28. Richardson MA, Morgan EE, Vielhauer MJ, Cuevas CA, Buondonno LM, Keane TM. Utility of the HIV dementia scale in assessing risk for significant HIV-related cognitive-motor deficits in a high-risk urban adult sample. AIDS Care 2005; 17(8):1013-1021.
  29. Morgan EE, Woods SP, Scott JC, Childers M, Beck JM, Ellis RJ, et al. Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol 2008; 30(1):83-90.
  30. Smith CA, van Gorp WG, Ryan ER, Ferrando SJ, Rabkin J. Screening subtle HIV-related cognitive dysfunction: the clinical utility of the HIV dementia scale. J Acquir Immune Defic Syndr 2003; 33(1):116-118.
  31. Forstein M, al. e. GUIDELINE WATCH: Practice Guidelines for the Treatment of Patients with HIV/AIDS. . American Psychiatric Association Available at: http://wwwpsychiatryonlinecom/pracGuide/PracticePDFs/Hiv-Aidswatchpdf


  1. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23(11):1359-1366.
  2. Gates TM, Cysique LA, Siefried KJ, Chaganti J, Moffat KJ, Brew BJ. Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder. AIDS 2016; 30(4):591-600.
  3. van Dyck CH, McMahon TJ, Rosen MI, O’Malley SS, O’Connor PG, Lin CH, et al. Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: a pilot study. J Neuropsychiatry Clin Neurosci 1997; 9(1):29-36.
  4. Fernandez F, Adams F, Levy JK, Holmes VF, Neidhart M, Mansell PW. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics 1988; 29(1):38-46.
  5. Evidence is mounting that HIV infection accelerates aging process. Clinicians need to emphasize wellness. AIDS Alert 2011; 26(3):25-27.
  6. Decloedt EH, Freeman C, Howells F, Casson-Crook M, Lesosky M, Koutsilieri E, et al. Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine (Baltimore) 2016; 95(46):e5401.
  7. Fazeli PL, Woods SP, Heaton RK, Umlauf A, Gouaux B, Rosario D, et al. An active lifestyle is associated with better neurocognitive functioning in adults living with HIV infection. J Neurovirol 2014; 20(3):233-242.
  8. Fernandez F, Adams F, K Levy J, F Holmes V, Neidhart M, W Mansell P. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics 1988; 29(1):38-46.
  9. Vance D, Fazeli P, Shacka J, Nicholson W, McKie P, Raper J, et al. Testing a Computerized Cognitive Training Protocol in Adults Aging With HIV-Associated Neurocognitive Disorders: Randomized Controlled Trial Rationale and Protocol. JMIR Res Protoc 2017; 6(4):e68.
  10. Ownby RL, Acevedo A. A pilot study of cognitive training with and without transcranial direct current stimulation to improve cognition in older persons with HIV-related cognitive impairment. Neuropsychiatr Dis Treat 2016; 12:2745-2754.
  11. Moore RC, Fazeli PL, Jeste DV, Moore DJ, Grant I, Woods SP, et al. Successful cognitive aging and health-related quality of life in younger and older adults infected with HIV. AIDS Behav 2014; 18(6):1186-1197.

General Disclaimer: HIV-Age.org is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through HIV-Age.org should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.